Back to MPT Database

Novel mAb contraceptive + TDF IVR

Formulation of a novel, nonhormonal contraceptive agent based on a multivalent monoclonal antibody (mAb) that blocks sperm from swimming through mucus and accessing the egg with antiretroviral (ARV) agents with demonstrated clinical efficacy in preventing HIV in a behavior-monitoring IVR.

Development Stage:

Preclinical – Early (Pre1)

Hormonal/Non-Hormonal:

Non-Hormonal

Delivery Route & Method:

Topical - Intravaginal Ring (IVR)

Mechanism of Action:

Nucleoside analogue reverse transcriptase inhibitor (NRTI) and sperm agglutinating antibody

Developer:

  • Oak Crest Institute of Science
  • University of North Carolina, Chapel Hill

Funding:

  • Nat. Institute Child Health & Human Development (NICHD)

Funding Mechanism:

NICHD: R01

Active Ingredient(s):

  • Monoclonal Antibodies
  • Tenofovir Disoproxil Fumarate (TDF)

Product Indication(s):

  • HIV
  • Pregnancy

Back to MPT Database